Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age12 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• 80 patients with confirmed metastatic tumor (>2.5 cm in short axis) will be enrolled, all ≥ 12 years of age with ECOG ≤ 2. All genders and races will be included.
• Inclusion Criteria:
• Histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer
• One to two metastases in non-brain sites that are amenable to LATTICE radiotherapy: >2.5 cm in short axis (dimension on axial imaging that is perpendicular to the longest dimension); bone metastasis can be included if the extraosseous component is >2.5 cm in short axis
• Age ≥12
• ECOG Performance Status 0-2
• For patients age 12-16, Lansky Play-Performance score 50-100
• Negative serum or urine pregnancy test within 2 weeks prior to enrollment of people of childbearing potential
• All patients and/or their parents or legal guardians must sign a written informed consent. For any child less than 18 years of age, assent must also be obtained in addition to parental or legal guardian consent.

You cannot join if

• Prior radiation therapy to the tumor to be treated
• Active pregnancy
• Diseases that place the patient at high risk of radiation complications including lupus, scleroderma, Li Fraumeni syndrome
• The tumor to be treated is from a hematologic malignancy such as lymphoma or myeloma

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• LATTICE Radiotherapy (Radiation): 5-fraction LATTICE radiotherapy delivered to 20 Gy with a simultaneous integrated boost (SIB) to 66.7 Gy.
• Standard radiotherapy (Radiation): Standard radiotherapy delivered to 25 Gy in 5 fractions.

Randomized · Single Group · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• radiation: Part of the study plan

Main goals

• Percent Tumor Volume Reduction Following Radiotherapy (90 +/- 20 days following radiotherapy)

Planned enrollment: 80 (estimated).

• Stanford University, Palo Alto, California

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT07594431

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Sep 8, 2026. Public record; not medical advice.